Investors
corporate profile
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
stock
snapshot
Additional stock info »
snapshot
02.25.2021 | 1:43 PM EST
Copyright West LLC. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.

Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors.